Boston Scientific Corporation $BSX Shares Sold by Ameriprise Financial Inc.

Ameriprise Financial Inc. decreased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 0.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,786,959 shares of the medical equipment provider’s stock after selling 64,744 shares during the period. Ameriprise Financial Inc.’s holdings in Boston Scientific were worth $838,114,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. 1248 Management LLC purchased a new stake in shares of Boston Scientific during the first quarter worth about $26,000. FWL Investment Management LLC purchased a new position in Boston Scientific in the second quarter valued at about $26,000. Sound Income Strategies LLC grew its stake in Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares in the last quarter. Kilter Group LLC acquired a new stake in Boston Scientific during the 2nd quarter valued at approximately $30,000. Finally, Princeton Global Asset Management LLC purchased a new stake in Boston Scientific during the 2nd quarter worth approximately $32,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on BSX shares. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, October 8th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $124.00 price target on shares of Boston Scientific in a report on Wednesday, October 22nd. Wells Fargo & Company raised their price objective on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Canaccord Genuity Group reissued a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a research report on Thursday, October 23rd. Finally, Erste Group Bank lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Buy” and an average price target of $124.43.

Boston Scientific Stock Performance

Shares of BSX stock opened at $92.58 on Friday. The company has a market cap of $137.24 billion, a P/E ratio of 49.51, a PEG ratio of 1.85 and a beta of 0.67. The business has a 50 day moving average of $98.85 and a two-hundred day moving average of $101.64. Boston Scientific Corporation has a 52 week low of $85.98 and a 52 week high of $109.50. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. During the same period in the prior year, the firm earned $0.63 EPS. The business’s quarterly revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director directly owned 24,134 shares of the company’s stock, valued at $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 143,095 shares of company stock worth $14,228,950. 0.50% of the stock is owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.